Tasso Announces Launch of Tasso Care® for Prescreening
Washingtoner/10247375

SEATTLE ~ Seattle, WA - Tasso, Inc., a leading provider of patient-centric blood collection solutions, has announced the launch of their new service, Tasso Care® for Prescreening. This end-to-end solution aims to improve the success of prescreening programs by expanding on the company's expertise in remote blood collection and analysis.

Tasso Care for Prescreening is specifically designed to support the prescreening of participants in clinical trials for various cardiometabolic and serostatus markers. The company plans to add additional panels for immunology, cardiovascular disease, and other therapeutic areas throughout the first quarter of 2024 as validation protocols are completed.

According to Tasso CEO and Co-Founder Ben Casavant, PhD, screening participants is a major bottleneck in drug development that often leads to trial delays and high screen failure rates. With Tasso Care, this process is revolutionized by replacing time-consuming clinic visits with convenient and automated prescreening testing at scale.

More on Washingtoner

• Pavillon 30 Years of Addiction Recovery in Western North Carolina, Earns National Accreditation
• Safer Spokane
• Spokane: Special Investigation Unit Seized Large Amounts of Cash and Cocaine
• Spokane: U.S. Conference of Mayors, American Beverage Foundation Visit Youth Wellness Zone
• Spokane: Disabled Smoke Alarm Contributes to Fatal Tiki Lodge Fire

By offering a virtually painless blood draw experience from the comfort of home, Tasso aims to increase clinical trial engagement rates by simplifying the operational process and optimizing the participants' experience. This also ensures a high-quality sample is returned to the lab. Additionally, Tasso Care allows for large populations to be screened simultaneously anytime and anywhere, ultimately increasing trial access and diversity.

Casavant believes that accelerating and expanding access to clinical trials is crucial in improving healthcare. He states that trials often face enrollment delays due to difficulties in identifying rare populations and obtaining up-to-date data. With Tasso Care for Prescreening, these challenges can be overcome as screening becomes more scalable and convenient.

It should be noted that Tasso Care for Prescreening is intended for use under institutional review board (IRB)-reviewed prescreening protocols. To learn more about this new service from Tasso Inc., please visit their website at www.tassoinc.com/prescreening.

---

Show All News | Disclaimer | Report Violation